Takeda Takes Collaborative, Educational Approach In Thai Dengue Initiative
Ties Up With Kao
Executive Summary
As it looks to roll out its new dengue vaccine globally, Takeda will work with Kao’s Thai subsidiary on education and prevention activities in Bangkok, later expanding these to wider areas of Thailand, in the first such local collaboration by the private sector.
You may also be interested in...
Takeda Pulls US BLA For Dengue Vaccine
Despite a priority review being granted late last year by the FDA, Takeda has announced the surprise withdrawal of the US BLA for its dengue vaccine TAK-003, for reasons it said centered on "data collection" issues. The quadrivalent vaccine has already been approved as Qdenga in several other markets including the EU, Indonesia and Thailand and the future path in the US is currently uncertain.
Takeda Eyes Further Filings For Dengue Vaccine But Timings Unclear
With Qdenga’s US approval process moving ahead with the granting of a Priority Review and the dengue vaccine's first market launch, in Indonesia, expected early next year, Takeda has recently referred to plans to expand the product into other countries as well. But precise timings as yet remain unclear.
Codagenix Eyes '23 Nasal RSV Vaccine Readout As GSK, Pfizer Set To Establish Lead
Codagenix hopes a 2023 data readout from its intranasal RSV vaccine will be an inflection point, even as GSK and Pfizer look to establish a lead in the segment. Meanwhile, a second cancer candidate has been added to Codagenix's preclinical pipeline and data for its COVID-19 vaccine and TNBC oncolytic virus are expected next year, CEO J Robert Coleman tells Scrip.